

MARKET ANNOUNCEMENT

Uscom - Johnson & Johnson Innovation Company of the Year

SYDNEY, Australia, 30th October 2014: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**), a revenue stage, cardiovascular medical devices company, today announced to the market it had been awarded the Johnson & Johnson Innovation Industry Excellence Company of the Year Award for 2014 at the Annual AusBiotech Life Sciences Conference.

The Award recognises established biotechnology companies that have demonstrated significant achievements and covers companies working in the fields of biotechnology or life sciences, including but not limited to the medical diagnostics or devices, pharmaceutical and agricultural sectors. Criteria for the award includes transactions, product pipeline, IP, Company strategy and /or revenue.

The award was presented to Dr Rob Phillips, CEO and founder of Uscom Limited, by Dr Dong Wu, Head of the Johnson & Johnson, Asia Pacific Innovation Centre, and Kathy Connell, the Director of New Ventures, ANZ, Johnson & Johnson, Asia Pacific Innovation Centre.

Executive Chairman of Uscom, Dr Rob Phillips said *"It is a great privilege to be recognised with this Johnson & Johnson Innovation Industry Excellence Company of the Year award. This award acknowledges the many individual efforts, over time, that have contributed to the growth of our Australian Biotechnology Company. While our mission is to save lives through commercialisation of cost effective medical devices, the corporate model for Uscom is excellence in business, built on excellence in science for the benefit of global health, and we are delighted to have these goals endorsed by receiving this award."*

About Johnson & Johnson Innovation

The Asia Pacific Innovation Center is part of Johnson & Johnson Innovation, a division of Johnson & Johnson (China) Investment Ltd. Johnson & Johnson Innovation focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit: www.jnjinnovation.com.

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way cardiovascular diseases are diagnosed and treated. The devices have specific application in hypertension, heart failure and sepsis, and improve the use of fluid, inotropes and vasoactive therapies.

Links:

<http://www.jnjinnovation.com>

<http://www.jnjinnovation.com/APIC%20Release.pdf>

**Uscom Limited**

ABN 35 091 028 090

Suite 1, Level 7, 10 Loftus Street

Sydney NSW 2000 Australia

T +612 9247 4144 F +612 9247 8157

www.uscom.com.au

MARKET ANNOUNCEMENT

About Uscom

Uscom Limited (UCM) is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the Uscom BP+. Both devices are clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects abnormalities and guides treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, heart failure, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Blood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Executive Chairman
rob@uscom.com.au
Ph: +61 2 9247 4144

Catherine Officer
Company Secretary
secretary@uscom.com.au